乙型肝炎病毒包膜M蛋白的表达与免疫原性研究
|
摘要
乙肝病毒(HBV)包膜蛋白由3个区域组成：与肝细胞直接作用的含有108或119个氨基酸残基的preS1，通过多聚白蛋白间接与之作用的含有55个氨基酸残基的preS2区域，和含有226个氨基酸残基的S蛋白区。许多研究证明，带有preS1和preS2序列的乙肝表面抗原(HBsAg)有望成为新一代更高效的乙肝疫苗。巴斯德毕赤酵母(Pichia pastoris)是近年兴起的一个重组蛋白生产系统，以其独特的优势在生物工程应用中不断得到推广。本论文就HBV包膜M蛋白在原核大肠杆菌(E．coli)和真核Pichia系统的表达、性质鉴定及免疫原性等进行了系统详细的研究。
在原核系统中表达preS2多肽，为HBV包膜M蛋白的活性检测提供材料。将人工合成preS2的全基因插入E．coli表达载体pThioHisA，以硫氧还蛋白融合蛋白的形式实现高效表达。经渗透压处理初步纯化蛋白，获得了具有preS2抗原性的thioredoxin-preS2融合蛋白。
为了在Pichia系统中高效表达HBV包膜M蛋白，用限制性内切酶SacI+SalI消化质粒pPIC3.5k和pAO815，替换对等部分，组成新的毕赤酵母高拷贝整合型表达载体pAO818。用它构建表达HBV包膜S蛋白的重组质粒，获得稳定的高表达。证实新载体改建成功后，将M蛋白编码基因插入酵母整合型表达质粒pAO818的醇氧化酶(AOX1)启动子下游，构建携带8拷贝M表达盒的重组载体，经电转化SMD1168菌株和G418筛选，得到了高效分泌表达M蛋白的毕赤酵母菌株，表达量达到50mg／L。通过CsC1等密度梯度离心的初步纯化，分泌型重组M蛋白具有preS2和S抗原性，可以形成大小在22nm左右的颗粒，并具有一定程度的糖基化。
E．coli系统表达的thioredoxin-preS2融合蛋白和Pichia系统分泌表达的HBV包膜M蛋白颗粒的免疫原性研究表明，实验组小鼠均出现抗-preS2阳性，其抗体水平明显高于对照组；与细胞免疫相关的γ干扰素水
The hepatitis B virus (HBV) envelope (env) protein is composed of three regions: the 108- or 119-residue preS1 region involved in the direct interaction with hepatocytes, the 55-residue preS2 region associated with the polymerized albumin-mediated interaction, and the major 226-residue S protein region. Many studies have provided evidence that hepatitis B surface antigen (HBsAg) including preSl and preS2 sequences could be an ideal candidate for a new HBV vaccine with higher efficacy. The methylotrophic yeast Pichia pastoris has been developed as production systems for recombinant proteins recently. The favourable and most advantageous characteristics of the species have resulted in an increasing number of biotechnological applications.
To determine the activity of HBV env protein M, polypeptide preS2 was expressed in prokaryotic system. A gene coding for preS2 was artificially synthesized. The gene was subcloned into Escherichia coli expression vector pThioHisA and expressed at high level as a fusion protein of thioredoxin. The thioredoxin-preS2 fusion protein was initial purified by the treatment of osmotic pressure, displayed preS2 antigenicity.
To express HBV env protein M at a high level in P. pastoris, the same segments of pPIC3.5k and pAO815 digested with restriction enzyme SacI and SalI were exchanged to obtain the new vector pAO818. Genes of HBV env protein S was placed in this vector and expressed at sable and high level. After success in reconstruction of this high level expression vector, gene of HBV env protein M was placed under the control of AOX1 promoter in this integrative Pichia expression vector carrying eight copies of the expression cassette. Through electroporation transformation of SMD1168 and G418 selection, a strain of Pichia pastoris capable of secreting protein M into the
在原核系统中表达preS2多肽，为HBV包膜M蛋白的活性检测提供材料。将人工合成preS2的全基因插入E．coli表达载体pThioHisA，以硫氧还蛋白融合蛋白的形式实现高效表达。经渗透压处理初步纯化蛋白，获得了具有preS2抗原性的thioredoxin-preS2融合蛋白。
为了在Pichia系统中高效表达HBV包膜M蛋白，用限制性内切酶SacI+SalI消化质粒pPIC3.5k和pAO815，替换对等部分，组成新的毕赤酵母高拷贝整合型表达载体pAO818。用它构建表达HBV包膜S蛋白的重组质粒，获得稳定的高表达。证实新载体改建成功后，将M蛋白编码基因插入酵母整合型表达质粒pAO818的醇氧化酶(AOX1)启动子下游，构建携带8拷贝M表达盒的重组载体，经电转化SMD1168菌株和G418筛选，得到了高效分泌表达M蛋白的毕赤酵母菌株，表达量达到50mg／L。通过CsC1等密度梯度离心的初步纯化，分泌型重组M蛋白具有preS2和S抗原性，可以形成大小在22nm左右的颗粒，并具有一定程度的糖基化。
E．coli系统表达的thioredoxin-preS2融合蛋白和Pichia系统分泌表达的HBV包膜M蛋白颗粒的免疫原性研究表明，实验组小鼠均出现抗-preS2阳性，其抗体水平明显高于对照组；与细胞免疫相关的γ干扰素水
The hepatitis B virus (HBV) envelope (env) protein is composed of three regions: the 108- or 119-residue preS1 region involved in the direct interaction with hepatocytes, the 55-residue preS2 region associated with the polymerized albumin-mediated interaction, and the major 226-residue S protein region. Many studies have provided evidence that hepatitis B surface antigen (HBsAg) including preSl and preS2 sequences could be an ideal candidate for a new HBV vaccine with higher efficacy. The methylotrophic yeast Pichia pastoris has been developed as production systems for recombinant proteins recently. The favourable and most advantageous characteristics of the species have resulted in an increasing number of biotechnological applications.
To determine the activity of HBV env protein M, polypeptide preS2 was expressed in prokaryotic system. A gene coding for preS2 was artificially synthesized. The gene was subcloned into Escherichia coli expression vector pThioHisA and expressed at high level as a fusion protein of thioredoxin. The thioredoxin-preS2 fusion protein was initial purified by the treatment of osmotic pressure, displayed preS2 antigenicity.
To express HBV env protein M at a high level in P. pastoris, the same segments of pPIC3.5k and pAO815 digested with restriction enzyme SacI and SalI were exchanged to obtain the new vector pAO818. Genes of HBV env protein S was placed in this vector and expressed at sable and high level. After success in reconstruction of this high level expression vector, gene of HBV env protein M was placed under the control of AOX1 promoter in this integrative Pichia expression vector carrying eight copies of the expression cassette. Through electroporation transformation of SMD1168 and G418 selection, a strain of Pichia pastoris capable of secreting protein M into the
引文
1．姚桢．分子乙型肝炎病毒相关病学．北京：中国医药科技出版社．1998
2．金奇．医学分子病毒学．北京：科学出版社．2001．325～347
3. Carman W, Thomas H and Domingo E. Viral genetic vanation: hepatitis B virus as a clinical example. Lancet. 1993, 341: 349～353
4．成军，杨守纯．现代肝炎病毒分子生物学．北京：人民军医出版社．1997
5. Wunderlich G and Bruss V. Characterization of early hepatitis B virus surface protein oligomers. Arch Virol. 1996, 141: 1191～1205
6. Chiou HL, Lee TS, Kuo J, et al. Altered antigenicity of 'a'determinant variants of hepatitis B virus. Journal of General Virology. 1997, 78: 2639～2645
7. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et al. Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000.60(2): 113～121
8．房德兴．乙型肝炎表面抗原aa126位——一个特殊的抗原位点．免疫学杂志．1998，14(2)：127～128
9．汪春义，叶世德，陈万革，等．糖基化对乙型肝炎表面抗原疫苗的影响．微生物学免疫学进展．2000，28(2)：31～34
10. Bruss V, Gerhardt E, Viehif K, et al. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996, 39: 23～31
11. Poisson F, Severae A, Hourioux C, et al. Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology. 1997, 228: 115～120
12. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. Journal of Virology. 1997, 71(12): 9350～9357
13. Neurath AR, Kent SB and Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science. 1984,224(4647): 392～395
14. Mangold CMT, Unckell F, Werr M, et al. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol. 1997, 142: 2257～226715. Satoh O, Imai H, Yoneyama T, et al. Membrane structure of the hepatitis B virus surface antigen particle. J Biochem. 2000, 127: 543～550
16. Oess S and Hildt E. Novel cell permeable motif derived from the preS2-domain of hepatitis B virus surface antigens. Gene Therapy. 2000, 7: 750～758
17. Lu XY, Mehta AA, Dwek RM, et al. Evicence that N-linked glycosyation is necessary for hepatitis B virus secretion. Virology. 1995, 213: 660～665
18. Klinkert MQ, Theilmann L, Pfaff E, et al. Pre-Sl antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol. 1986, 58(2): 522～525
19. Vento S, Rondanelli EG, Ranieri S, et al. Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B. Lancet.
20. Milich D R. T- and B-cell recognition of hepatitis B viral antigen. Immunology Today. 1988, 9: 380～386
21. Koziel MJ. Immunology of viral hepatitis. Am J Med. 1996, 100: 98～109
22. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990, 8(Suppl): S69～73
23. del Canho R, Grosheide PM, Voogd M, et al. lmmunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol. 1993, 41(1): 30～34
24．贾雪塘，史久华．全球乙型肝炎免疫接种状况．国外医学：预防、诊断、治疗用的生物制品分册．1997，20(2)：59～60
25．李东升，封秀红．乙肝疫苗的长期效果和复种问题的研究进展．河南预防医学杂志．1997，8(2)：122～124
26．阮力，汪垣，强伯勤．新型疫苗研究的现状与展望．学苑出版社．1992．68
27. Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-SHBs antibody induction in responder mice. Vaccine. 1999, 17: 2528～2537
28. Yamada T, Iwabuki H, kanno T, et al. Physicochemicai and immunological characterization of hepatitis B Virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine. 2001, 19: 3154～3163
29. Bertino JS, Jr., Tirrell P, et al. A comparative trial of standard or high-dose S subunit recombinant hapatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2??particles for revaccination of healthy adult nonresponders. The Journal of Infectious Diseases. 1997, 175: 678～681
30．朱运峰．乙肝核心抗原与外源抗原决定簇融合的基因工程肽苗研究进展．生物工程进展．1994，14(4)：42～45
31. Moynihan JS and Howard CR. Recent Advances in the development of peptide vaccines for hepatitis B. Intervirology. 2001, 44: 65～77
32. Michel ML and Delphine Loirat. DNA vaccines for prophylactic or theraprutic immunization against hepatitis B. Intervirology. 2001, 44: 78～87
33．闻玉梅．治疗性疫苗的研究进展．中华微生物学和免疫学杂志．1996，16(3)：155～158
34. Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000, 16(1): 23～52
35. Cereghino JL and Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000, 24(1): 45～66
36. Hollenberg CP and Gellissen G. Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997, 8(5): 554～560
37. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999, 30: 193～200
38. Ausubel FM, Kingston RE, Seidman JG, et al. Short Protocols in Molecular Biology, 3rd ed., John Wiley&Sons, Inc. 1995
39．琦祖和，熊伟军，袁建刚，等．乙型肝炎病毒adr NC-1 DNA的全顺序测定．中国科学(B辑)．1988，(12)：1300～1304
40. Sambrook J, Fritsch EF and Maniatis T. Molecular Cloning: A Laboratory Manual, 2rd ed., New York: Cold Spring Harbor Laboratory Press, 1989.
41. Hardy E, Martinez E, Diago D, et al. Large-scale production of recombinant hepatitis B surface antigen from Pichiapastoris. Journal of Biotechnology. 2000, 77: 157～167
42. Vassileva A, Chugh DA, Swaminathan S, et al. Expression of Hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. J Biotechnol. 2001, 88: 21～35
43. Vassileva A, Chugh DA, Swaminathan S, et al. Effect of copy number on expression levels of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris. Protein Expression and Purification. 2001, 21: 71～8044．杨剑莹，惠静毅，李光地，等．带有preS的重组乙肝表面抗原在毕赤酵母中的表达．生物化学与生物物理学报．2000，32(2)：139～144
45．谢云飞，沈心亮，李文辉．乙型肝炎病毒包膜M蛋白在巴斯德毕赤酵母中的表达．微生物学免疫学进展．2000，28(3)：8～10
46．杨剑莹，金菁，孔玉英，等．毕赤酵母表达的重组乙肝表面抗原SS1的纯化及性质鉴定．生物化学与生物物理学报．2000，32(5)：503～508
47. Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene, 1997, 190(1): 55～62
48．蔡良婉，王年，蒋尉，等．adr亚型乙肝病毒基因组全克隆以及其表面抗原基因的次级克隆．中国医学科学院学报．1984，6(4)：252～255
49. Multi-Copy Pichia Expression Kit-A Manual of Methods for the Isolation and Expression of Recombinant Proteins from Pichia Pastoris Strains Containing Multiple Copies ofa Partecular Gene. From www. invitrogen. com
50. Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (NY). 1991, 9(5): 455～460
51. Clare JJ, Romanos MA, Rayment FB, et al. Production of mouse epidermal growth factor in yeast: high-level secretion using Pichia pastoris strains containing multiple gene copies. Gene. 1991, 105(2): 205～212
52. Pichia Fermentation Process Guidelines. From www.invitrogen.com
53. Schmitt S, Glebe D, Alving K, et al. Analysis of the pre-S2 N- and O-Linked Glycans of the M Surface Protein from Human Hepatitis B Virus. The Journal of Biological Chemistry. 1999, 274(17): 11945～11957
54. Romamos MA, Scorer CA and Clare JJ. Foreign gene expression in yeast: a review. Yeast. 1992, 8(6): 423～488
55. Tleugabulova D, Falcon V, Sewer M, et al. Aggregation of recombinant hepatitis B surface antigen in Pichia pastoris. Journal of Chromatographv B. 1998, 716: 209～219
56．陈建萍．冷冻对基因乙肝疫苗(HBsAg)抗原性的影响．现代预防医学．1999，26(1)：77～78
57．吴冠芸，潘华珍，吴辉．生物化学与分子生物学实验常用数据手册．北京：科学??出版社．1999．94
58．陈惠黎，王克夷．糖复合物的结构和功能．上海：上海医科大学出版社．1997．17
59. Monsigny M, Petit C and Roche AC. Colorimetrie determination of neutral sugars by a resorcinol sulfuric acid micromethod. Analytical Biochemistry. 1988, 175: 525～530
60. Hui JY, Li GD, Kong YY, et al. Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Journal of Biotechnology. 1999, 72: 49～59
61．朱立平，陈学清．免疫学常用实验法．北京：人民军医出版社．2000．
62. Jilg W. Novel hepatitis B vaccines. Vaccine. 1998: S65～S68
63. Neurath AR, Kent SB, Strick N, et al. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986, 46(3): 429～436
64. Zukerman AJ. Active immunization/Polypeptide and newer hepatitis B vaccines. In: Hepatitis, Edited by Gerety RJ. 1985. 414
65．刘文军，杨芙蓉，阮力，等．乙型肝炎表面抗原S—蛋白糖化位点序列的人工变异及其哺乳动物表达产物的性状研究．病毒学报．1997，13(1)：33～40
66．叶琳，刘敦员，赵田，等．两种配方的氢氧化铝吸附基因工程乙肝疫苗的效果比较．微生物免疫学进展．1999，27(4)：51～54
67．于善谦，王洪海，朱乃硕，等．免疫学导论．北京：高等教育出版社&施普林格出版社．1999．
68. Sun B, Rizzo LV, Sun SH, et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-1ike response. J Immunol. 1997, 159(2): 1004-1011
69. Abbas AK, Murphy KM and Sher A. Functional diversity of helper T lymphocytes. Nature. 1996, 383: 787～793
70. Milich DR, McLachlan A and Thornton GB. T-cell recognition ofpre-S regions of HBsAg can bypass nonresponse to the S region. Adv Exp Med Biol. 1987, 225: 233～2391．汤秀明，王培林．乙型肝炎的遗传学研究进展．国外医学：遗传学分册．1996，19(2)：67～70
2．姚桢．分子乙型肝炎病毒相关病学．北京：中国医药科技出版社．1998
3．金奇．医学分子病毒学．北京：科学出版社．2001．325～347
4. Carman W, Thomas H and Domingo E. Viral genetic vanation: hepatitis B virus as a clinical example. Lancet. 1993, 341: 349～353
5. Ganem D and Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem. 1987, 56: 651～693
6．成军，杨守纯．现代肝炎病毒分子生物学．北京：人民军医出版社．1997
7. Wunderlich G andBruss V. Characterization of early hepatitis B virus surface protein??oligomers. Arch Virol. 1996, 141: 1191～1205
8. Bruss V and Ganem D. The role of envelope protein in hepatitis B virus assembly. Proc Natl Acad Sci U S A. 1991, 88: 1059～1063
9. Stirk H J, Thornton JM and Howard CR. A Topological.Model for Hepatitis B Surface Antigen. Intervirology. 1992, 33: 148～158
10. Gillece-castro BL, Fisher S J, Tarention AL, et al. Structure of the Oligosaccharide Portion of Human Hepatitis B Surface Antigen. Arch Biochem Biophy. 87, 256(1): 194～201
11. Hanaoka K, Takasaki S, Kobata A, et al. Structure of Asparagine-Linked Sugar Chains in the Major Polypeptide of Hepatitis B Surface Antigen. J Biochem. 1986, 99: 1273～1276
12. Mangold CMT, Unckell F, Werr M, et al. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol. 1997, 142: 2257～2267
13. Satoh O, Imai H, Yoneyama T, et al. Membrane structure of the hepatitis B virus surface antigen particle. J Biochem. 2000, 127: 543～550
14. Chiou HL, Lee TS, Kuo J, et al. Altered antigenicity of 'a'determinant variants of hepatitis B virus. Journal of General Virology. 1997, 78: 2639～2645
15. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et aL Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000, 60(2): 113～121
16. Ashton-Rickardt PG and Murray K. Mutations that change the immunloigical subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determinant. J Med Virol. 1989, 29: 204～214
17. Okamoto H, Imai M, Miyakawa Y, et al. Site-directec mutagenesis of hepatitis B surface antigen sequence at codon 160 from arginine to lysine for conversion of subtype determinant from r to w. Biochem Biophys Res Commun. 1987, 148: 500～504
18．房德兴．乙型肝炎表面抗原aa126位——一个特殊的抗原位点．免疫学杂志．1998，14(2)：127～128
19．孙剑，侯金林，陈金军．乙肝病毒S基因变异研究进展．国外医学：病毒学分册．1999，6(3)：84～8820. Schmitt S, Glebe D, Alving K, et al. Analysis of the pre-S2 N- and O-Linked Glycans of the M Surface Protein from Human Hepatitis B Virus. The Journal of Biological Chemistry. 1999, 274(17): 11945～11957
21. Lu XY, Mehta AA, Dwek RM, et al. Evicence that N-linked glycosyation is necessary for hepatitis B virus secretion. Virology. 1995, 213: 660～665
22. Pontisso P, Petit MA, Bankowski M J, et al. Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol. 1989, 63(5): 1981～1988
23. Pontisso P, Ruvoletto MG, Gerlich WH, et al. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology. 1989, 173(2): 522～530
24. Saul FA, Normand BV, Lema F, et al. Crystal structure of a dominant B-cell epitope from the preS2 region of hepatitis B virus in the form of an inserted peptide segment in maltodextrin-binding protein. J Mol Biol. 1998, 280: 185～192
25. Meisel H, Sominskaya I, Pumpens P, et al. Fine maping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus. Intervirology. 1994, 37: 330～339
26. Milich D R. T- and B-cell recognition of hepatitis B viral antigen. Immunology Today. 1988, 9: 380～386
27. Oess S and Hildt E. Novel cell permeable motif derived from the preS2-domain of hepatitis B virus surface antigens. Gene Therapy. 2000, 7: 750～758
28. Sobotta D, Sominskaya I, Jansons J, et al. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. Journal of General Virology. 2000, 81: 369～378
29. Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterisation of a new recombinant pre-S 1, pre-S2 and SHBs antigen-SHBs antibody induction in responder mice. Vaccine. 1999, 17: 2528～2537
30. Yamada T, Iwabuki H, kanno T, et al. Physicochemical and immunological characterization of hepatitis B Virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine. 2001, 19: 3154～3163
31. Bertino JS, Jr., Tirrell P, et al. A comparative trial of standard or high-dose S subunit??recombinant hapatitis B vaccine versus a vaccine containing S subunit, pre-Sl, and pre-S2 particles for revaccination of healthy adult nonresponders. The Journal of Infectious Diseases. 1997,175:678-681
32. Milich DR. Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens. Immunological Reviews. 1987,99:71-103
33. Bruss V, Gerhardt E, Viehif K, et ah Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996,39:23-31
34. Poisson F, Severac A, Hourioux C, et al. Both pre-Sl and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology. 1997,228:115-120
35. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. Journal of Virology. 1997,71(12):9350~9357
36. Klinkert MQ, Theilmann L, Pfaff E, et al. Pre-Sl antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol. 1986,58(2):522~525
37. Vento S, Rondanelli EG, Ranieri S, et ah Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B. Lancet. 1987,2(8551):119-122
38. Milich DR, McLachlan A and Thornton GB. T-cell recognition of pre-S regions of HBsAg can bypass nonresponse to the S region. Adv Exp Med Biol. 1987,225:233-239
39. Mabit H, Dubanchet S, Capel F, et ah In vitro infection of human hepatitis B virus (HBV): spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences. J Gen Virol. 1994,75(10):2681-2689
40. Neurath AR, Kent SB and Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science. 1984,224(4647):392~395
41. 张定凤. 乙型肝炎抗病毒治疗的新进展. 中华肝脏杂志, 1999,7(1):1-2
42. Hoofnagle JH and Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997,336:347-356
43. Clercq ED. Perspectives for the treatment of hepatitis B virus infections. International Journal of Antimicrobial Agents. 1999,12:81-95
44. Lo KJ, Lee SD, Tsai YT, et ah Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HbcAg-positive HBsAg-carrier mothers. Hepatology.1998, 8: 1647～1650
45. Foruin M, Chotard J, Jack AD, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 1993, 341: 1129～1131
46. Whittle HC, Maine N, Pilkington J, et al. Long term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 1995, 345: 1089～1092
47. Vellinga A, van Damme P, Weyler J J, et al. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 1999, 17: 602～606
48. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis. 1994, 169:1374～1376
49. Carmen WF, Zanetti AR, Karyiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990, 336: 325～329
50. Harrison T J, Hopes EA, Oon C J, et al. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol. 1991,13(suppl 4): S105～S107
51. Kane A, Lloyd J, Zaffran M, et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ. 1999, 77: 801～807
52. Diminsky D, Moav N, Gorecki M, et al. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine. 2000, 18: 3～17
53. Otto BF, Suarnawa IM, Stewart T, et al. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine. 2000, 18: 498～502
54. Sutanto A, Suarnawa IM, Nelson CM, et al. Home delivery of heat-stable vaccines in Indonesia: Outreach immunization with a prefilled single-use injection device. Bull World Health Organ. 1999, 77: 119～126
55. Brazolot MCL, Weeratna R, Kreg AM, et al. CpG DNA can induce strong THI humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998, 95: 15553～15558
56．王佑春，李河民，胡宗汉．不同来源HBsAg的氨基酸组成及糖基化程度的比较．中华微生物学与免疫学杂志．1991，11(4)：205～20757．张瑾，王文栋．乙肝疫苗的研究概况．生物学通报．1998，33(7)：26～27
58. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990, 8(Suppl): S69～73
59. del Canho R, Grosheide PM, Voogd M, et al. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol. 1993, 41(1): 30～34
60. Grotto I, Mandel Y, Ephros M, et al. Major adverse reactions to yeast-derived hepatitis B vaccines--a review. VacCine. 1998, 16(4): 329～334
61. Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982, 298(5872): 347～350.
62. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999, 30: 193～200
63. Gizaris V, Roumeliotou A, Ktenas E, et al. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules. Vaccine. 1993, 11 (14): 1445～1447
64．任贵方，阮薇琴，田淑芳，等．乙型肝炎病毒表面抗原主蛋白基因转基因细胞系的建立与细胞性质的研究．病毒学报．1991，7：112-119
65．梅雅芳，任贵方，朱既明．基因工程乙型肝炎病毒表面抗原(HBsAg)连续纯化流程的的建立．病毒学报．1990，6：305～311
66．杨进业，李荣成，王树声．乙型肝炎病毒基因重组疫苗研究近况．广西预防医学．1997，3(1)：41～44
67. Moriarty AM, Hoyer BH, Shih JW, et al. Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector. Proc Natl Acad Sci USA. 1981, 78(4): 2606～2610
68. Wang Y, Stratowa C, Schaefer-Ridder M, et al. Enhanced production of hepatitis B surface antigen in NIH 3T3 mouse fibroblasts by using extrachromosomally replicating bovine papillomavirus vector. Mol Cell Biol. 1983, 3(6): 1032～1039
69. Diminsky D, Schirmbeck R, Reimann J, et al. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 1997, 15(6/7): 637～64770. Smith GL, Mackett M and Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983, 302(5908): 490～495
71. Lanford RE, Luckow V, Kennedy RC, et al. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J Virol. 1989, 63(4): 1549～1557
72．张德礼．人类腺病毒用作重组疫苗和基因治疗载体的优势与前景．中华实验和临床病毒学杂志．1995，9(2)：190～193
73. Tacket CO, Losonsky G, Lubeck MD, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine. 1992, 10(10): 673～4576
74. Bradbury J. Anthony Monaco: tackling complex genetics head on. Lancet. 2000, 356(9242): 1662
75．林炳亮，姚集鲁，高志良．乙型肝炎疫苗的研究进展．国外医学：内科学分册．199926(2)：51～53
76. Koziel MJ. Immunology of viral hepatitis. Am J Med. 1996, 100: 98～109
77. Jones CD, Page M, Bacon A, et al. Caracterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagenen~(TM)); evidence for superior anti-SHBs antibody induction in responder mice. J Viral Hepat. 1998, 5(suppl 2): 5～8
78. Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985, 228: 1195～1199
79. McDernott AB, Cohen SBA, Zuckerman JN, et al. Human leukocyte antigens imfluence the immune response to a pre-S/S hepatitis B vaccine. Vaccine. 1999, 17: 330～339
80. Pride MW, Bailey CR, Muchmore E, et al. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene~R, a hepatitis B vaccine containing pre-S 1, pre-S2 and S gene products. Vaccine. 1998, 16: 543～550
81．惠静毅，李光地，孔玉英，等．一种改造的同时含有preS1，preS2抗原决定簇的乙肝病毒表面抗原．中国科学(C辑)．1998，28(2)：122～128
82. Hui JY, Li GD, Kong YY, et al. Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Journal of Biotechnology. 1999. 72: 49～5983. Jilg W. Novel hepatitis B vaccines. Vaccine. 1998, 16: S65-S68
84．朱运峰．乙肝核心抗原与外源抗原决定簇融合的基因工程肽苗研究进展．生物工程进展．1994，14(4)：42～45
85. Moynihan JS and Howard CR. Recent Advances in the development of peptide vaccines for hepatitis B. Intervirology. 2001, 44: 65～77
86．刘茂昌，吴玉章，朱锡华，等．乙肝病毒新型免疫原性多肽的设计、合成．免疫学杂志．1998，14(2)：98～100
87. Michel ML and Delphine Loirat. DNA vaccines for prophylactic or theraprutic immunization against hepatitis B. Intervirology. 2001, 44: 78～87
88．袁正宏，方听，郑玲洁，等．免疫途径及载体对乙肝病毒DNA疫苗免疫效果影响的研究．中华微生物学和免疫学杂志．1999，19(1)：25～28
89．惠静毅，李光地，孔玉英，等．带有preS抗原决定簇的乙肝表面抗原的DNA免疫研究．科学通报．1999，44(2)：168～171
90．张涛，曾霞，王树声．乙肝DNA疫苗的研究进展．广西预防医学．200l，7(3)：177～180
91．闻玉梅．治疗性疫苗的研究进展．中华微生物学和免疫学杂志．1996，16(3)：155～158
92. Wen YM, Guo SQ, Zhong W, et al. Enhanced immunogenicity in mice with hepatitis B vaccine complexed to human hepatitis B immunoglobulin. Chinese Medical Journal. 1994, 107: 741～744
93．周生华，瞿涤，闻玉梅，等．抗HBs-HBsAg复合物诱生体液免疫应答的研究．中华微生物学和免疫学杂志．1998，18(4)：331～335
94．周生华，闻玉梅．乙型肝炎病毒表面抗原．抗体复合物对抗原的加工递呈与诱生细胞因子的作用．病毒学报．1997，13(3)：269～2711. Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000, 16(1): 23～52
2. Cereghino JL and Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000, 24(1): 45～66
3. Hollenberg CP and Gellissen G. Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997, 8(5): 554～560
4. Romamos MA, Scorer CA and Clare JJ. Foreign gene expression in yeast: a review. Yeast. 1992, 8(6): 423～4885. van der Kler IJ, Harder W and Veenhuis M. Biosynthesis and assembly of alcohol oxidase, a peroxisomal matrix protein in methylotrophic yeast: a review. Yeast. 1991, 7(3): 195～209
6. Veenhuis M, van Dijken JP and Harder W. The significance of peroxisomes in the metabolism of one-carbon compounds in yeast. Adv Microb Physiol. 1983, 24: 1～82
7. Egli T, van Dijken JP, Veenhuis M, et al. Methanol metabolism in yeasts: regulation of the synthesis of catabolic enzymes. Arch Microbiol. 1980, 124: 115～121
8. de Hoop MJ and Ab G. Import of proteins into peroxisomes and other microbodies. Biochem J. 1992, 286(Pt 3): 657～669
9. Subramani S. Protein import into peroxisomes and biogenesis of the organelle. Ann Rev Cell Biol. 1993, 9: 445～478
10. Cregg JM and Higgins DR. Production of foreign proteins in the yeast Pichia pastoris. Can J Bot. 1995, 73(suppl 1): S981～S987
11. Titorenko VI, Waterham HR, Cregg JM, et al. Peroxisome biogenesis in the yeast Hansenula polymorpha is controlled by a complex set of interacting gene products. Proc Natl Acad Sci USA. 1993, 90(16): 7470～7474
12. Cregg. JM, Madden KR, Barringer K J, et al. Functional characterization of the two alcihol oxidase genes from the yeast Pichiapastoris. Mol Cell Biol. 1989, 9: 1316～1323
13. Tschopp JF, Brust PF, Cregg JM, et al. Expression of the LacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res. 1987, 15: 3859～3876
14．赵翔，霍克克，李育阳．毕赤酵母的密码子用法分析．生物工程学报，2000，16(3)：308～311
15. Morel N and Massoulie J. Expression and processing of vertebrate acetylcholinesterase in the yeast Pichia pastoris. Biochem J. 1997, 328(Pt1): 121～129
16. Weiss HM, Haase W, Michel H, et al. Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995, 377(3): 451～456.
17. Waterham HR, Digan ME, Koutz PJ, et al. Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. Gene. 1997, 186: 37～4418. Shen S, Suiter G, Jeffries TW, et al. A stong nitrogen souree-regulated promoter for controlled expressionof foreign genes in the yeast Pichia pastoris. Gene. 1998,216:93-102
19. Cereghino GP and Cregg JM. Applications of yeast in biotechnology: protein production and genetic analysis. Curr Opin Biotechnol. 1999,10(5):422~427 20. Cregg JM, Vedvick TS and Raschke WC. Recent Advances in the expression of foreign genes in Pichia pastoris. Bio/Technology. 1993,11(8):905~910
21. Higgins DR and Cregg JM. Introduction to Pichia pastoris. Methods in Molecular Biology. 1998,103:1-15
22. Van der Kiel IJ, Hilbrands RE, Swaving GJ, et al The Hansenula polymorpha PER3 gene is essential for the import of PTS1 proteins into the peroxisomal matrix. J Biol Chem. 1995,270(29): 17229-17236
23. Suiter GJ, Looyenga L, Veenhuis M, Harder W. Occurrence of peroxisomal membrane proteins in methylotrophic yeasts grown under different conditions. Yeast. 1990,6(1):35~43.
24. Barr KA, Hopkins SA and Sreekrishna K. Protocol for efficient secretion of HAS developed from Pichia pastoris. Pharm Eng. 1992,12:48-51
25. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999,30:193-200
26. Gemmill TR and Trimble RB. Overview of N- and O-linked oligsaccharide structures found in various yeast species. Biochimica et Biophysica Acta. 1999,1426:227-237
27. Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene. 1997,190(1):55~62
28. Vassileva A, Chugh DA, Swaminathan S, et al. Effect of copy number on the expression levels of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris. Protein Expr Purif. 2001,21(1):71-80
29. Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N Y). 1991,9(5):455~460
30. Romanos MA, Clare J J, Beesley KM, et al. Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties. Vaccine. 1991, 9(12): 901～906
31. Clare JJ, Romanos MA, Rayment FB, et al. Production of mouse epidermal growth factor in yeast: high-level secretion using Pichia pastoris strains containing multiple gene copies. Gene. 1991, 105(2): 205～212
2．金奇．医学分子病毒学．北京：科学出版社．2001．325～347
3. Carman W, Thomas H and Domingo E. Viral genetic vanation: hepatitis B virus as a clinical example. Lancet. 1993, 341: 349～353
4．成军，杨守纯．现代肝炎病毒分子生物学．北京：人民军医出版社．1997
5. Wunderlich G and Bruss V. Characterization of early hepatitis B virus surface protein oligomers. Arch Virol. 1996, 141: 1191～1205
6. Chiou HL, Lee TS, Kuo J, et al. Altered antigenicity of 'a'determinant variants of hepatitis B virus. Journal of General Virology. 1997, 78: 2639～2645
7. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et al. Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000.60(2): 113～121
8．房德兴．乙型肝炎表面抗原aa126位——一个特殊的抗原位点．免疫学杂志．1998，14(2)：127～128
9．汪春义，叶世德，陈万革，等．糖基化对乙型肝炎表面抗原疫苗的影响．微生物学免疫学进展．2000，28(2)：31～34
10. Bruss V, Gerhardt E, Viehif K, et al. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996, 39: 23～31
11. Poisson F, Severae A, Hourioux C, et al. Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology. 1997, 228: 115～120
12. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. Journal of Virology. 1997, 71(12): 9350～9357
13. Neurath AR, Kent SB and Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science. 1984,224(4647): 392～395
14. Mangold CMT, Unckell F, Werr M, et al. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol. 1997, 142: 2257～226715. Satoh O, Imai H, Yoneyama T, et al. Membrane structure of the hepatitis B virus surface antigen particle. J Biochem. 2000, 127: 543～550
16. Oess S and Hildt E. Novel cell permeable motif derived from the preS2-domain of hepatitis B virus surface antigens. Gene Therapy. 2000, 7: 750～758
17. Lu XY, Mehta AA, Dwek RM, et al. Evicence that N-linked glycosyation is necessary for hepatitis B virus secretion. Virology. 1995, 213: 660～665
18. Klinkert MQ, Theilmann L, Pfaff E, et al. Pre-Sl antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol. 1986, 58(2): 522～525
19. Vento S, Rondanelli EG, Ranieri S, et al. Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B. Lancet.
20. Milich D R. T- and B-cell recognition of hepatitis B viral antigen. Immunology Today. 1988, 9: 380～386
21. Koziel MJ. Immunology of viral hepatitis. Am J Med. 1996, 100: 98～109
22. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990, 8(Suppl): S69～73
23. del Canho R, Grosheide PM, Voogd M, et al. lmmunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol. 1993, 41(1): 30～34
24．贾雪塘，史久华．全球乙型肝炎免疫接种状况．国外医学：预防、诊断、治疗用的生物制品分册．1997，20(2)：59～60
25．李东升，封秀红．乙肝疫苗的长期效果和复种问题的研究进展．河南预防医学杂志．1997，8(2)：122～124
26．阮力，汪垣，强伯勤．新型疫苗研究的现状与展望．学苑出版社．1992．68
27. Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-SHBs antibody induction in responder mice. Vaccine. 1999, 17: 2528～2537
28. Yamada T, Iwabuki H, kanno T, et al. Physicochemicai and immunological characterization of hepatitis B Virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine. 2001, 19: 3154～3163
29. Bertino JS, Jr., Tirrell P, et al. A comparative trial of standard or high-dose S subunit recombinant hapatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2??particles for revaccination of healthy adult nonresponders. The Journal of Infectious Diseases. 1997, 175: 678～681
30．朱运峰．乙肝核心抗原与外源抗原决定簇融合的基因工程肽苗研究进展．生物工程进展．1994，14(4)：42～45
31. Moynihan JS and Howard CR. Recent Advances in the development of peptide vaccines for hepatitis B. Intervirology. 2001, 44: 65～77
32. Michel ML and Delphine Loirat. DNA vaccines for prophylactic or theraprutic immunization against hepatitis B. Intervirology. 2001, 44: 78～87
33．闻玉梅．治疗性疫苗的研究进展．中华微生物学和免疫学杂志．1996，16(3)：155～158
34. Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000, 16(1): 23～52
35. Cereghino JL and Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000, 24(1): 45～66
36. Hollenberg CP and Gellissen G. Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997, 8(5): 554～560
37. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999, 30: 193～200
38. Ausubel FM, Kingston RE, Seidman JG, et al. Short Protocols in Molecular Biology, 3rd ed., John Wiley&Sons, Inc. 1995
39．琦祖和，熊伟军，袁建刚，等．乙型肝炎病毒adr NC-1 DNA的全顺序测定．中国科学(B辑)．1988，(12)：1300～1304
40. Sambrook J, Fritsch EF and Maniatis T. Molecular Cloning: A Laboratory Manual, 2rd ed., New York: Cold Spring Harbor Laboratory Press, 1989.
41. Hardy E, Martinez E, Diago D, et al. Large-scale production of recombinant hepatitis B surface antigen from Pichiapastoris. Journal of Biotechnology. 2000, 77: 157～167
42. Vassileva A, Chugh DA, Swaminathan S, et al. Expression of Hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. J Biotechnol. 2001, 88: 21～35
43. Vassileva A, Chugh DA, Swaminathan S, et al. Effect of copy number on expression levels of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris. Protein Expression and Purification. 2001, 21: 71～8044．杨剑莹，惠静毅，李光地，等．带有preS的重组乙肝表面抗原在毕赤酵母中的表达．生物化学与生物物理学报．2000，32(2)：139～144
45．谢云飞，沈心亮，李文辉．乙型肝炎病毒包膜M蛋白在巴斯德毕赤酵母中的表达．微生物学免疫学进展．2000，28(3)：8～10
46．杨剑莹，金菁，孔玉英，等．毕赤酵母表达的重组乙肝表面抗原SS1的纯化及性质鉴定．生物化学与生物物理学报．2000，32(5)：503～508
47. Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene, 1997, 190(1): 55～62
48．蔡良婉，王年，蒋尉，等．adr亚型乙肝病毒基因组全克隆以及其表面抗原基因的次级克隆．中国医学科学院学报．1984，6(4)：252～255
49. Multi-Copy Pichia Expression Kit-A Manual of Methods for the Isolation and Expression of Recombinant Proteins from Pichia Pastoris Strains Containing Multiple Copies ofa Partecular Gene. From www. invitrogen. com
50. Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (NY). 1991, 9(5): 455～460
51. Clare JJ, Romanos MA, Rayment FB, et al. Production of mouse epidermal growth factor in yeast: high-level secretion using Pichia pastoris strains containing multiple gene copies. Gene. 1991, 105(2): 205～212
52. Pichia Fermentation Process Guidelines. From www.invitrogen.com
53. Schmitt S, Glebe D, Alving K, et al. Analysis of the pre-S2 N- and O-Linked Glycans of the M Surface Protein from Human Hepatitis B Virus. The Journal of Biological Chemistry. 1999, 274(17): 11945～11957
54. Romamos MA, Scorer CA and Clare JJ. Foreign gene expression in yeast: a review. Yeast. 1992, 8(6): 423～488
55. Tleugabulova D, Falcon V, Sewer M, et al. Aggregation of recombinant hepatitis B surface antigen in Pichia pastoris. Journal of Chromatographv B. 1998, 716: 209～219
56．陈建萍．冷冻对基因乙肝疫苗(HBsAg)抗原性的影响．现代预防医学．1999，26(1)：77～78
57．吴冠芸，潘华珍，吴辉．生物化学与分子生物学实验常用数据手册．北京：科学??出版社．1999．94
58．陈惠黎，王克夷．糖复合物的结构和功能．上海：上海医科大学出版社．1997．17
59. Monsigny M, Petit C and Roche AC. Colorimetrie determination of neutral sugars by a resorcinol sulfuric acid micromethod. Analytical Biochemistry. 1988, 175: 525～530
60. Hui JY, Li GD, Kong YY, et al. Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Journal of Biotechnology. 1999, 72: 49～59
61．朱立平，陈学清．免疫学常用实验法．北京：人民军医出版社．2000．
62. Jilg W. Novel hepatitis B vaccines. Vaccine. 1998: S65～S68
63. Neurath AR, Kent SB, Strick N, et al. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986, 46(3): 429～436
64. Zukerman AJ. Active immunization/Polypeptide and newer hepatitis B vaccines. In: Hepatitis, Edited by Gerety RJ. 1985. 414
65．刘文军，杨芙蓉，阮力，等．乙型肝炎表面抗原S—蛋白糖化位点序列的人工变异及其哺乳动物表达产物的性状研究．病毒学报．1997，13(1)：33～40
66．叶琳，刘敦员，赵田，等．两种配方的氢氧化铝吸附基因工程乙肝疫苗的效果比较．微生物免疫学进展．1999，27(4)：51～54
67．于善谦，王洪海，朱乃硕，等．免疫学导论．北京：高等教育出版社&施普林格出版社．1999．
68. Sun B, Rizzo LV, Sun SH, et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-1ike response. J Immunol. 1997, 159(2): 1004-1011
69. Abbas AK, Murphy KM and Sher A. Functional diversity of helper T lymphocytes. Nature. 1996, 383: 787～793
70. Milich DR, McLachlan A and Thornton GB. T-cell recognition ofpre-S regions of HBsAg can bypass nonresponse to the S region. Adv Exp Med Biol. 1987, 225: 233～2391．汤秀明，王培林．乙型肝炎的遗传学研究进展．国外医学：遗传学分册．1996，19(2)：67～70
2．姚桢．分子乙型肝炎病毒相关病学．北京：中国医药科技出版社．1998
3．金奇．医学分子病毒学．北京：科学出版社．2001．325～347
4. Carman W, Thomas H and Domingo E. Viral genetic vanation: hepatitis B virus as a clinical example. Lancet. 1993, 341: 349～353
5. Ganem D and Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem. 1987, 56: 651～693
6．成军，杨守纯．现代肝炎病毒分子生物学．北京：人民军医出版社．1997
7. Wunderlich G andBruss V. Characterization of early hepatitis B virus surface protein??oligomers. Arch Virol. 1996, 141: 1191～1205
8. Bruss V and Ganem D. The role of envelope protein in hepatitis B virus assembly. Proc Natl Acad Sci U S A. 1991, 88: 1059～1063
9. Stirk H J, Thornton JM and Howard CR. A Topological.Model for Hepatitis B Surface Antigen. Intervirology. 1992, 33: 148～158
10. Gillece-castro BL, Fisher S J, Tarention AL, et al. Structure of the Oligosaccharide Portion of Human Hepatitis B Surface Antigen. Arch Biochem Biophy. 87, 256(1): 194～201
11. Hanaoka K, Takasaki S, Kobata A, et al. Structure of Asparagine-Linked Sugar Chains in the Major Polypeptide of Hepatitis B Surface Antigen. J Biochem. 1986, 99: 1273～1276
12. Mangold CMT, Unckell F, Werr M, et al. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol. 1997, 142: 2257～2267
13. Satoh O, Imai H, Yoneyama T, et al. Membrane structure of the hepatitis B virus surface antigen particle. J Biochem. 2000, 127: 543～550
14. Chiou HL, Lee TS, Kuo J, et al. Altered antigenicity of 'a'determinant variants of hepatitis B virus. Journal of General Virology. 1997, 78: 2639～2645
15. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et aL Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000, 60(2): 113～121
16. Ashton-Rickardt PG and Murray K. Mutations that change the immunloigical subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determinant. J Med Virol. 1989, 29: 204～214
17. Okamoto H, Imai M, Miyakawa Y, et al. Site-directec mutagenesis of hepatitis B surface antigen sequence at codon 160 from arginine to lysine for conversion of subtype determinant from r to w. Biochem Biophys Res Commun. 1987, 148: 500～504
18．房德兴．乙型肝炎表面抗原aa126位——一个特殊的抗原位点．免疫学杂志．1998，14(2)：127～128
19．孙剑，侯金林，陈金军．乙肝病毒S基因变异研究进展．国外医学：病毒学分册．1999，6(3)：84～8820. Schmitt S, Glebe D, Alving K, et al. Analysis of the pre-S2 N- and O-Linked Glycans of the M Surface Protein from Human Hepatitis B Virus. The Journal of Biological Chemistry. 1999, 274(17): 11945～11957
21. Lu XY, Mehta AA, Dwek RM, et al. Evicence that N-linked glycosyation is necessary for hepatitis B virus secretion. Virology. 1995, 213: 660～665
22. Pontisso P, Petit MA, Bankowski M J, et al. Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol. 1989, 63(5): 1981～1988
23. Pontisso P, Ruvoletto MG, Gerlich WH, et al. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology. 1989, 173(2): 522～530
24. Saul FA, Normand BV, Lema F, et al. Crystal structure of a dominant B-cell epitope from the preS2 region of hepatitis B virus in the form of an inserted peptide segment in maltodextrin-binding protein. J Mol Biol. 1998, 280: 185～192
25. Meisel H, Sominskaya I, Pumpens P, et al. Fine maping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus. Intervirology. 1994, 37: 330～339
26. Milich D R. T- and B-cell recognition of hepatitis B viral antigen. Immunology Today. 1988, 9: 380～386
27. Oess S and Hildt E. Novel cell permeable motif derived from the preS2-domain of hepatitis B virus surface antigens. Gene Therapy. 2000, 7: 750～758
28. Sobotta D, Sominskaya I, Jansons J, et al. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. Journal of General Virology. 2000, 81: 369～378
29. Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterisation of a new recombinant pre-S 1, pre-S2 and SHBs antigen-SHBs antibody induction in responder mice. Vaccine. 1999, 17: 2528～2537
30. Yamada T, Iwabuki H, kanno T, et al. Physicochemical and immunological characterization of hepatitis B Virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine. 2001, 19: 3154～3163
31. Bertino JS, Jr., Tirrell P, et al. A comparative trial of standard or high-dose S subunit??recombinant hapatitis B vaccine versus a vaccine containing S subunit, pre-Sl, and pre-S2 particles for revaccination of healthy adult nonresponders. The Journal of Infectious Diseases. 1997,175:678-681
32. Milich DR. Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens. Immunological Reviews. 1987,99:71-103
33. Bruss V, Gerhardt E, Viehif K, et ah Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996,39:23-31
34. Poisson F, Severac A, Hourioux C, et al. Both pre-Sl and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology. 1997,228:115-120
35. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. Journal of Virology. 1997,71(12):9350~9357
36. Klinkert MQ, Theilmann L, Pfaff E, et al. Pre-Sl antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol. 1986,58(2):522~525
37. Vento S, Rondanelli EG, Ranieri S, et ah Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B. Lancet. 1987,2(8551):119-122
38. Milich DR, McLachlan A and Thornton GB. T-cell recognition of pre-S regions of HBsAg can bypass nonresponse to the S region. Adv Exp Med Biol. 1987,225:233-239
39. Mabit H, Dubanchet S, Capel F, et ah In vitro infection of human hepatitis B virus (HBV): spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences. J Gen Virol. 1994,75(10):2681-2689
40. Neurath AR, Kent SB and Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science. 1984,224(4647):392~395
41. 张定凤. 乙型肝炎抗病毒治疗的新进展. 中华肝脏杂志, 1999,7(1):1-2
42. Hoofnagle JH and Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997,336:347-356
43. Clercq ED. Perspectives for the treatment of hepatitis B virus infections. International Journal of Antimicrobial Agents. 1999,12:81-95
44. Lo KJ, Lee SD, Tsai YT, et ah Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HbcAg-positive HBsAg-carrier mothers. Hepatology.1998, 8: 1647～1650
45. Foruin M, Chotard J, Jack AD, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 1993, 341: 1129～1131
46. Whittle HC, Maine N, Pilkington J, et al. Long term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 1995, 345: 1089～1092
47. Vellinga A, van Damme P, Weyler J J, et al. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 1999, 17: 602～606
48. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis. 1994, 169:1374～1376
49. Carmen WF, Zanetti AR, Karyiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990, 336: 325～329
50. Harrison T J, Hopes EA, Oon C J, et al. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol. 1991,13(suppl 4): S105～S107
51. Kane A, Lloyd J, Zaffran M, et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ. 1999, 77: 801～807
52. Diminsky D, Moav N, Gorecki M, et al. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine. 2000, 18: 3～17
53. Otto BF, Suarnawa IM, Stewart T, et al. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine. 2000, 18: 498～502
54. Sutanto A, Suarnawa IM, Nelson CM, et al. Home delivery of heat-stable vaccines in Indonesia: Outreach immunization with a prefilled single-use injection device. Bull World Health Organ. 1999, 77: 119～126
55. Brazolot MCL, Weeratna R, Kreg AM, et al. CpG DNA can induce strong THI humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998, 95: 15553～15558
56．王佑春，李河民，胡宗汉．不同来源HBsAg的氨基酸组成及糖基化程度的比较．中华微生物学与免疫学杂志．1991，11(4)：205～20757．张瑾，王文栋．乙肝疫苗的研究概况．生物学通报．1998，33(7)：26～27
58. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990, 8(Suppl): S69～73
59. del Canho R, Grosheide PM, Voogd M, et al. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol. 1993, 41(1): 30～34
60. Grotto I, Mandel Y, Ephros M, et al. Major adverse reactions to yeast-derived hepatitis B vaccines--a review. VacCine. 1998, 16(4): 329～334
61. Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982, 298(5872): 347～350.
62. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999, 30: 193～200
63. Gizaris V, Roumeliotou A, Ktenas E, et al. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules. Vaccine. 1993, 11 (14): 1445～1447
64．任贵方，阮薇琴，田淑芳，等．乙型肝炎病毒表面抗原主蛋白基因转基因细胞系的建立与细胞性质的研究．病毒学报．1991，7：112-119
65．梅雅芳，任贵方，朱既明．基因工程乙型肝炎病毒表面抗原(HBsAg)连续纯化流程的的建立．病毒学报．1990，6：305～311
66．杨进业，李荣成，王树声．乙型肝炎病毒基因重组疫苗研究近况．广西预防医学．1997，3(1)：41～44
67. Moriarty AM, Hoyer BH, Shih JW, et al. Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector. Proc Natl Acad Sci USA. 1981, 78(4): 2606～2610
68. Wang Y, Stratowa C, Schaefer-Ridder M, et al. Enhanced production of hepatitis B surface antigen in NIH 3T3 mouse fibroblasts by using extrachromosomally replicating bovine papillomavirus vector. Mol Cell Biol. 1983, 3(6): 1032～1039
69. Diminsky D, Schirmbeck R, Reimann J, et al. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 1997, 15(6/7): 637～64770. Smith GL, Mackett M and Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983, 302(5908): 490～495
71. Lanford RE, Luckow V, Kennedy RC, et al. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J Virol. 1989, 63(4): 1549～1557
72．张德礼．人类腺病毒用作重组疫苗和基因治疗载体的优势与前景．中华实验和临床病毒学杂志．1995，9(2)：190～193
73. Tacket CO, Losonsky G, Lubeck MD, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine. 1992, 10(10): 673～4576
74. Bradbury J. Anthony Monaco: tackling complex genetics head on. Lancet. 2000, 356(9242): 1662
75．林炳亮，姚集鲁，高志良．乙型肝炎疫苗的研究进展．国外医学：内科学分册．199926(2)：51～53
76. Koziel MJ. Immunology of viral hepatitis. Am J Med. 1996, 100: 98～109
77. Jones CD, Page M, Bacon A, et al. Caracterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagenen~(TM)); evidence for superior anti-SHBs antibody induction in responder mice. J Viral Hepat. 1998, 5(suppl 2): 5～8
78. Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985, 228: 1195～1199
79. McDernott AB, Cohen SBA, Zuckerman JN, et al. Human leukocyte antigens imfluence the immune response to a pre-S/S hepatitis B vaccine. Vaccine. 1999, 17: 330～339
80. Pride MW, Bailey CR, Muchmore E, et al. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene~R, a hepatitis B vaccine containing pre-S 1, pre-S2 and S gene products. Vaccine. 1998, 16: 543～550
81．惠静毅，李光地，孔玉英，等．一种改造的同时含有preS1，preS2抗原决定簇的乙肝病毒表面抗原．中国科学(C辑)．1998，28(2)：122～128
82. Hui JY, Li GD, Kong YY, et al. Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Journal of Biotechnology. 1999. 72: 49～5983. Jilg W. Novel hepatitis B vaccines. Vaccine. 1998, 16: S65-S68
84．朱运峰．乙肝核心抗原与外源抗原决定簇融合的基因工程肽苗研究进展．生物工程进展．1994，14(4)：42～45
85. Moynihan JS and Howard CR. Recent Advances in the development of peptide vaccines for hepatitis B. Intervirology. 2001, 44: 65～77
86．刘茂昌，吴玉章，朱锡华，等．乙肝病毒新型免疫原性多肽的设计、合成．免疫学杂志．1998，14(2)：98～100
87. Michel ML and Delphine Loirat. DNA vaccines for prophylactic or theraprutic immunization against hepatitis B. Intervirology. 2001, 44: 78～87
88．袁正宏，方听，郑玲洁，等．免疫途径及载体对乙肝病毒DNA疫苗免疫效果影响的研究．中华微生物学和免疫学杂志．1999，19(1)：25～28
89．惠静毅，李光地，孔玉英，等．带有preS抗原决定簇的乙肝表面抗原的DNA免疫研究．科学通报．1999，44(2)：168～171
90．张涛，曾霞，王树声．乙肝DNA疫苗的研究进展．广西预防医学．200l，7(3)：177～180
91．闻玉梅．治疗性疫苗的研究进展．中华微生物学和免疫学杂志．1996，16(3)：155～158
92. Wen YM, Guo SQ, Zhong W, et al. Enhanced immunogenicity in mice with hepatitis B vaccine complexed to human hepatitis B immunoglobulin. Chinese Medical Journal. 1994, 107: 741～744
93．周生华，瞿涤，闻玉梅，等．抗HBs-HBsAg复合物诱生体液免疫应答的研究．中华微生物学和免疫学杂志．1998，18(4)：331～335
94．周生华，闻玉梅．乙型肝炎病毒表面抗原．抗体复合物对抗原的加工递呈与诱生细胞因子的作用．病毒学报．1997，13(3)：269～2711. Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000, 16(1): 23～52
2. Cereghino JL and Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000, 24(1): 45～66
3. Hollenberg CP and Gellissen G. Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997, 8(5): 554～560
4. Romamos MA, Scorer CA and Clare JJ. Foreign gene expression in yeast: a review. Yeast. 1992, 8(6): 423～4885. van der Kler IJ, Harder W and Veenhuis M. Biosynthesis and assembly of alcohol oxidase, a peroxisomal matrix protein in methylotrophic yeast: a review. Yeast. 1991, 7(3): 195～209
6. Veenhuis M, van Dijken JP and Harder W. The significance of peroxisomes in the metabolism of one-carbon compounds in yeast. Adv Microb Physiol. 1983, 24: 1～82
7. Egli T, van Dijken JP, Veenhuis M, et al. Methanol metabolism in yeasts: regulation of the synthesis of catabolic enzymes. Arch Microbiol. 1980, 124: 115～121
8. de Hoop MJ and Ab G. Import of proteins into peroxisomes and other microbodies. Biochem J. 1992, 286(Pt 3): 657～669
9. Subramani S. Protein import into peroxisomes and biogenesis of the organelle. Ann Rev Cell Biol. 1993, 9: 445～478
10. Cregg JM and Higgins DR. Production of foreign proteins in the yeast Pichia pastoris. Can J Bot. 1995, 73(suppl 1): S981～S987
11. Titorenko VI, Waterham HR, Cregg JM, et al. Peroxisome biogenesis in the yeast Hansenula polymorpha is controlled by a complex set of interacting gene products. Proc Natl Acad Sci USA. 1993, 90(16): 7470～7474
12. Cregg. JM, Madden KR, Barringer K J, et al. Functional characterization of the two alcihol oxidase genes from the yeast Pichiapastoris. Mol Cell Biol. 1989, 9: 1316～1323
13. Tschopp JF, Brust PF, Cregg JM, et al. Expression of the LacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res. 1987, 15: 3859～3876
14．赵翔，霍克克，李育阳．毕赤酵母的密码子用法分析．生物工程学报，2000，16(3)：308～311
15. Morel N and Massoulie J. Expression and processing of vertebrate acetylcholinesterase in the yeast Pichia pastoris. Biochem J. 1997, 328(Pt1): 121～129
16. Weiss HM, Haase W, Michel H, et al. Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995, 377(3): 451～456.
17. Waterham HR, Digan ME, Koutz PJ, et al. Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. Gene. 1997, 186: 37～4418. Shen S, Suiter G, Jeffries TW, et al. A stong nitrogen souree-regulated promoter for controlled expressionof foreign genes in the yeast Pichia pastoris. Gene. 1998,216:93-102
19. Cereghino GP and Cregg JM. Applications of yeast in biotechnology: protein production and genetic analysis. Curr Opin Biotechnol. 1999,10(5):422~427 20. Cregg JM, Vedvick TS and Raschke WC. Recent Advances in the expression of foreign genes in Pichia pastoris. Bio/Technology. 1993,11(8):905~910
21. Higgins DR and Cregg JM. Introduction to Pichia pastoris. Methods in Molecular Biology. 1998,103:1-15
22. Van der Kiel IJ, Hilbrands RE, Swaving GJ, et al The Hansenula polymorpha PER3 gene is essential for the import of PTS1 proteins into the peroxisomal matrix. J Biol Chem. 1995,270(29): 17229-17236
23. Suiter GJ, Looyenga L, Veenhuis M, Harder W. Occurrence of peroxisomal membrane proteins in methylotrophic yeasts grown under different conditions. Yeast. 1990,6(1):35~43.
24. Barr KA, Hopkins SA and Sreekrishna K. Protocol for efficient secretion of HAS developed from Pichia pastoris. Pharm Eng. 1992,12:48-51
25. Bretthauer RK and Castellino FJ. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem. 1999,30:193-200
26. Gemmill TR and Trimble RB. Overview of N- and O-linked oligsaccharide structures found in various yeast species. Biochimica et Biophysica Acta. 1999,1426:227-237
27. Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene. 1997,190(1):55~62
28. Vassileva A, Chugh DA, Swaminathan S, et al. Effect of copy number on the expression levels of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris. Protein Expr Purif. 2001,21(1):71-80
29. Clare JJ, Rayment FB, Ballantine SP, et al. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N Y). 1991,9(5):455~460
30. Romanos MA, Clare J J, Beesley KM, et al. Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties. Vaccine. 1991, 9(12): 901～906
31. Clare JJ, Romanos MA, Rayment FB, et al. Production of mouse epidermal growth factor in yeast: high-level secretion using Pichia pastoris strains containing multiple gene copies. Gene. 1991, 105(2): 205～212